Advertisement

Vascular Changes and Diabetic Neuropathy

  • Rayaz A. Malik
  • Solomon Tesfaye
  • John D. Ward
Part of the Contemporary Cardiology book series (CONCARD)

Abstract

Human diabetic neuropathy is characterized by dysfunction of the somatic and autonomic nervous systems. A simple definition was recently agreed on at an international consensus meeting: “The presence of symptoms and/or signs of peripheral nerve dysfunction in people with diabetes after the exclusion of other causes” (1). The clinical manifestations, underlying pathology, and etiology of the diabetic neuropathies are varied. Classification has previously been based on pathologic and etiologic considerations, but a clinical classification of the neuropathies is favored (Table 1) (2). For research, epidemiologic, and clinical trial purposes, a more detailed definition that includes subclinical neuropathy is required (3,4). The Rochester Diabetic Neuropathy Study has established a paradigm for clinical trial design (3) that includes the following factors: (1) neuropathic symptoms (neuropathy symptom score [NSS]); (2) neuropathic deficits (neuropathy impairment score [NIS]); (3) motor/sensory nerve conduction velocity (MS NCV); (4) quantitative sensory testing (QST); and (5) autonomic function testing (AFT). The minimum criteria for a diagnosis of neuropathy required two or more abnormalities among the criteria listed, with at least one criterion including three or five. Staging was as follows: NO, no neuropathy (minimum criteria unfulfilled); Nl, asymptomatic neuropathy (NSS = 0); N2, symptomatic neuropathy; and N3, disabling neuropathy.

Keywords

Diabetic Neuropathy Sural Nerve Nerve Conduction Velocity Diabetic Peripheral Neuropathy Diabetic Polyneuropathy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Boulton AJM, Gries FA, Jervell JA. Guidelines for the diagnosis and outpatient management of diabetic peripheral neuropathy. Diabetic Med 1998;15:508–514.PubMedCrossRefGoogle Scholar
  2. 2.
    Thomas PK. Classification, differential diagnosis, and staging of diabetic peripheral neuropathy. Diabetes 1997;46(Suppl 2):S54–S57.Google Scholar
  3. 3.
    Dyck PJ, Kratz KM, Karnes JZ, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993;43:817–824.PubMedCrossRefGoogle Scholar
  4. 4.
    Dyck PJ, Melton J, O’Brien PC, et al. Approaches to improve epidemiological studies of diabetic neuropathy. Diabetes 1997;46(Suppl 2):55–58.Google Scholar
  5. 5.
    Young MJ, Boulton AJM, McLeod AF, et al. A multicentre study of the prevalence of diabetic peripheral neuropathy in the UK hospital clinic population. Diabetologia 1993;36:150–154.PubMedCrossRefGoogle Scholar
  6. 6.
    Tesfaye S, Stephens LK, Stephenson JM, et al. Prevalence of diabetic peripheral neuropathy and its relation to glycemic control and potential risk factors: the EURODIAB IDDM complications study. Diabetologia 1996;39:1377–1384.PubMedCrossRefGoogle Scholar
  7. 7.
    Cabezas-Cerrato J, for the Neuropathy Spanish Study Group of the Spanish Diabetes Society (SDS). The prevalence of clinical diabetic neuropathy in Spain: a study in primary care and hospital clinic groups. Diabetologia 1998;41:1263–1269.CrossRefGoogle Scholar
  8. 8.
    Partanen J, Niskanen L, Lehtinen J, et al. Natural history of peripheral neuropathy in patients with noninsulin dependent diabetes mellitus. N Engl J Med 1995;333:89–94.PubMedCrossRefGoogle Scholar
  9. 9.
    UKPDS. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998;352:837–853.CrossRefGoogle Scholar
  10. 10.
    Maser RE, Pfeifer MA, Dorman JS, et al. Diabetic autonomic neuropathy and cardiovascular risk: the Pittsburgh Epidemiology of Diabetic Complications Study III. Arch Intern Med 1990;150:1218–1222.PubMedCrossRefGoogle Scholar
  11. 11.
    DCCT Trial Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 1995;122:561–568.CrossRefGoogle Scholar
  12. 12.
    Hopf HC, Guttmann L. Diabetic third nerve palsy: evidence for a mesencephalic lesion. Neurology 1990;40:1041–1045.PubMedCrossRefGoogle Scholar
  13. 13.
    Schady W, Abuaisha B, Boulton AJM. Observations on severe ulnar neuropathy in diabetes. J Diabetes Complications 1998;12:128–132.PubMedCrossRefGoogle Scholar
  14. 14.
    Boulton AJM. What causes neuropathic pain? J Diabetes Complications 1992;6:58–63.PubMedCrossRefGoogle Scholar
  15. 15.
    Chaudhuri KR, Wren DR, Werring D, et al. Unilateral abdominal muscle herniation with pain: a distinctive variant of diabetic radiculopathy. Diabetic Med 1997;14:803–807.PubMedCrossRefGoogle Scholar
  16. 16.
    Coppack SW, Watkins PJ. The natural history of diabetic femoral neuropathy. Q J Med 1991;79:307–314.PubMedGoogle Scholar
  17. 17.
    PascoeMK,LowPA,WindebankAJ.Subacutediabeticproximalneuropathy.MayoClinProc1997;72: 1123–1132.Google Scholar
  18. 18.
    Llewelyn JG, Thomas PK, King RHM. Epineurial microvasculitis in proximal diabetic neuropathy. J Neurol 1998;245:159–165.PubMedCrossRefGoogle Scholar
  19. 19.
    Malik RA, Ghani M, Walker D, et al. Pathological studies in diabetic amyotrophy. Diabetes 1998;A64: 0250.Google Scholar
  20. 20.
    Boulton AJM, Malik RA. Diabetic neuropathy. Med Clin North Am 1998;82:909–929.PubMedCrossRefGoogle Scholar
  21. 21.
    Watkins PJ, Thomas PK. Diabetes mellitus and the nervous system. J Neurol Neurosurg Psychiatry 1998;65:620–632.PubMedCrossRefGoogle Scholar
  22. 22.
    Veves A, Webster L, Chen TF, et al. Aetiopathogenesis and management of impotence in diabetic males: four years’ experience from a combined clinic. Diabetic Med 1995;12:77–82.PubMedCrossRefGoogle Scholar
  23. 23.
    Tesfaye S, Ward JD. Clinical features of diabetic polyneuropathy. In: Veves A, ed. Clinical Management of Diabetic Neuropathy. Humana, Totowa, NJ, 1998, pp. 49–60.CrossRefGoogle Scholar
  24. 24.
    Young M J, Jones GC. Diabetic neuropathy: symptoms, signs and assessment. In: Boulton AJM, ed. Diabetic Neuropathy. Marius, Lancaster, 1997, pp. 41–61.Google Scholar
  25. 25.
    Pryce TD. On diabetic neuritis, with a clinical and pathological description of three cases of diabetic pseudo-tabes. Brain 1893;16:416.CrossRefGoogle Scholar
  26. 26.
    Woltman HW, Wilder RM. Diabetes mellitus pathological changes in the spinal cord and peripheral nerves. Arch Intern Med 1929;44:576–603.CrossRefGoogle Scholar
  27. 27.
    Said G, Goulon-Goeau C, Lacroix C, Moulonguet A. Nerve biopsy findings in different patterns of proximal diabetic neuropathy. Ann Neurol 1994;35:559–569.PubMedCrossRefGoogle Scholar
  28. 28.
    Asbury AK. Focal and multifocal neuropathies of diabetes. In: Dyck PJ, Thomas PK, Asbury AK, Winegrad AI, Porte D, eds. Diabetic Neuropathy. WB Saunders, Philadelphia, 1987, pp. 45–55.Google Scholar
  29. 29.
    Johnson PC, Doll SC, Cromey DW. Pathogenesis of diabetic neuropathy. Ann Neuro11986;19:450–457.Google Scholar
  30. 30.
    Dyck PJ, Karnes JL, O’Brien P, Okazaki H, Lias A, Engelstad J. The spatial distribution of fibre loss in diabetic polyneuropathy suggests ischaemia. Ann Neurol 1986;19:440–449.PubMedCrossRefGoogle Scholar
  31. 31.
    Dyck PJ, Lais A, Karnes JL, O’Brien P, Rizza R. Fibre loss is primary and multifocal in sural nerves in diabetic polyneuropathy. Ann Neurol 1986;19:425–439.PubMedCrossRefGoogle Scholar
  32. 32.
    Orlidge A, D’Amore PA. Inhibition of capillary endothelial cell growth by pericytes and smooth muscle cells. J Cell Biol 1987;105:1455–1462.PubMedCrossRefGoogle Scholar
  33. 33.
    Sugimoto K, Nishizawa Y, Horiuchi S, Yagihashi S. Localization in human diabetic peripheral nerve of N-carboxymethyllysine-protein adducts, an advanced glycation endproduct. Diabetologia 1997;40: 1380–1387.PubMedCrossRefGoogle Scholar
  34. 34.
    Tooke JE. A pathophysiological framework for the pathogenesis of diabetic microangiopathy. In: Tooke JE, ed. Diabetic Angiopathy. Arnold, London, 1999, pp. 187–194.Google Scholar
  35. 35.
    Cagliero E, Roth T, Roy S, Lorenzi M. Characteristics and mechanisms of high glucose induced overexpression of basement membrane components in cultured human endothelial cells. Diabetes 1991;40: 102–109.PubMedCrossRefGoogle Scholar
  36. 36.
    Walker D, Malik RA, Boulton AJM, Rayman G. Structural differences in skin between the arm and foot in normal subjects and diabetic patients. Diabetologia 1996;39:A266–A1011.Google Scholar
  37. 37.
    Arora S, Smakowski P, Frykberg RG, et al. Differences in foot and forearm skin microcirculation in diabetic patients with and without neuropathy. Diabetes Care 1998;21:1339–1344.PubMedCrossRefGoogle Scholar
  38. 38.
    Khder Y, Briancon S, Petermann R, et al. Shear stress abnormalities contribute to endothelial dysfunction in hypertension but not in type II diabetes. J Hypertens 1998;16:1619–1625.PubMedCrossRefGoogle Scholar
  39. 39.
    Sorensen VB, Rossing P, Tarnow L, Parving H-H, Norgaard T, Kastrup J. Effects of nisoldipine and lisinopril on microvascular dysfunction in hypertensive type I diabetes patients with nephropathy. Clin Sci 1998;95:709–717.PubMedCrossRefGoogle Scholar
  40. 40.
    Malik RA, Paniagua O, Shaw L, Austin C, Heagerty AM. Resistance vessel function and structure in normotensive patients with type 1 diabetes. Diabetologia 1999;42:A75–A271.Google Scholar
  41. 41.
    Giannattasio C, Failla M, Piperno A, et al. Early impairment of large artery structure and function in type 1 diabetes mellitus. Diabetologia 1999;42:987–994.PubMedCrossRefGoogle Scholar
  42. 42.
    Enderle M-D, Benda N, Schmuelling R-M, Haering HU, Pfohl M. Preserved endothelial function in IDDM patients, but not in NIDDM patients compared with healthy subjects. Diabetes Care 1998;21: 271–277.PubMedCrossRefGoogle Scholar
  43. 43.
    Veves A, Akbari CM, Primavera J, et al. Endothelial dysfunction and the expression of endothelial nitric oxide synthetase in diabetic neuropathy, vascular disease, and foot ulceration. Diabetes 1998;47: 457–463.PubMedCrossRefGoogle Scholar
  44. 44.
    Jude EB, Boulton AJM, Ferguson MWJ, Appleton I. The role of nitric oxide synthase isoforms and arginase in the pathogenesis of diabetic foot ulcers: possible modulatory effects by transforming growth beta 1. Diabetologia 1999;42:748–757.PubMedCrossRefGoogle Scholar
  45. 45.
    Malik RA, Newrick PG, Sharma AK, et al. Microangiopathy in human diabetic neuropathy: relationship between capillary abnormalities and the severity of neuropathy. Diabetologia 1989;32:92–102.PubMedCrossRefGoogle Scholar
  46. 46.
    Kihara M, Mitsui MK, Mitsui Y, et al. Altered vasoreactivity to angiotensin II in experimental diabetic neuropathy: role of nitric oxide. Muscle Nerve 1999;22:920–925.PubMedCrossRefGoogle Scholar
  47. 47.
    Hogikyan RV, Wald JJ, Feldman EL, Greene DA, Halter JB, Supiano MA. Acute effects of adrenergicmediated ischemia on nerve conduction in subjects with type 2 diabetes. Metabolism 1999;48:495–500.PubMedCrossRefGoogle Scholar
  48. 48.
    Forrest KYZ, Maser RE, Pambianco G, Becker DJ, Orchard TJ. Hypertension as a risk factor for diabetic neuropathy. Diabetes 1997;46:665–670.PubMedCrossRefGoogle Scholar
  49. 49.
    The EURODIAB Prospec tive Complica tions S tudy (PC S) Group. Cardiovascular risk factors predict diabetic peripheral neuropathy in type 1 subjects in Europe. Diabetologia 1999;42:A50–A181.Google Scholar
  50. 50.
    Rodriguez-Sanchez C, Medina Sanchez M, Malik RA, Ah-See AK, Sharma AK. Morphological abnormalities in the sural nerve from patients with peripheral vascular disease. Histol Histopathol 1991; 6:63–71.PubMedGoogle Scholar
  51. 51.
    Korthals JK, Gieron MA, Dyck PJ. Intima of epineurial arterioles is increased in diabetic polyneuropathy. Neurology 1988;38:1582–1586.PubMedCrossRefGoogle Scholar
  52. 52.
    Malik RA, Tesfaye S, Thompson SD, et al. Transperineurial capillary abnormalities in the sural nerve of patients with diabetic neuropathy. Microvas Res 1994;48:236–245.CrossRefGoogle Scholar
  53. 53.
    Fagerberg SE. Diabetic neuropathy: a clinical and histological study on the significance of vascular affections. Acta Med Scand 1959;164:5–81.Google Scholar
  54. 54.
    Giannini C, Dyck PJ. Basement membrane reduplication and pericyte degeneration precede development of diabetic polyneuropathy and are associated with its severity. Ann Neurol 1995;37:498–504.PubMedCrossRefGoogle Scholar
  55. 55.
    Malik RA, Veves A, Masson EA, et al. Endoneurial capillary abnormalities in mild human diabetic neuropathy. J Neurol Neurosurg Psychiatry 1992;55:557–561.PubMedCrossRefGoogle Scholar
  56. 56.
    Behse F, Bucthal F, Carlsen F. Nerve biopsy and conduction studies in diabetic neuropathy. J Neurol Neurosurg Psychiatry 1977;40:1072–1082.PubMedCrossRefGoogle Scholar
  57. 57.
    Malik RA, Tesfaye S, Thompson SD, et al. Endoneurial localisation of microvascular damage in human diabetic neuropathy. Diabetologia 1993;36:454–459.PubMedCrossRefGoogle Scholar
  58. 58.
    Yasuda H, Dyck PJ. Abnormalities of endoneurial microvessels and sural nerve pathology in diabetic neuropathy. Neurology 1987;37:20–28.PubMedCrossRefGoogle Scholar
  59. 59.
    Britland ST, Young RJ, Sharma AK, Clarke BF. Relationship of endoneurial capillary abnormalities to type and severity of diabetic polyneuropathy. Diabetes 1990;39:909–913.PubMedCrossRefGoogle Scholar
  60. 60.
    Dyck PJ, Giannini C. Pathologic alterations in the diabetic neuropathies of humans: a review. J Neuropathol Exp Neurol 1996;55:1181–1193.PubMedCrossRefGoogle Scholar
  61. 61.
    Timperley WR, Boulton AJM, Davies Jones GAB, Jarrat JA, Ward JD. Small vessel disease in progressive diabetic neuropathy associated with good metabolic control. J Clin Pathol 1985;38:1030–1038.PubMedCrossRefGoogle Scholar
  62. 62.
    Williams E, Timperly WR, Ward JD, Duckworth T. Electronmicroscopical studies of vessels in diabetic peripheral neuropathy. J Clin Pathol 1980;33:462–470.PubMedCrossRefGoogle Scholar
  63. 63.
    Dyck PJ, Hansen S. Karnes J, et al. Capillary number and percentage closed in human diabetic sural nerve. Proc Natl Acad Sci USA 1985;82:2513–2517.PubMedCrossRefGoogle Scholar
  64. 64.
    Malik RA, Masson EA, Sharma AK, et al. Hypoxic neuropathy: relevance to human diabetic neuropathy. Diabetologia 1990;33:311–318.PubMedCrossRefGoogle Scholar
  65. 65.
    Newrick PG, Wilson AJ, Jakubowski J, Boulton AJM, Ward JD. Sural nerve oxygen tension in diabetes. BMJ 1986;293:1053–1054.PubMedCrossRefGoogle Scholar
  66. 66.
    Ibrahim S, Harris ND, Radatz M, et al. A new minimally invasive technique to show nerve ischaemia in diabetic neuropathy. Diabetologia 1999;42:737–742.PubMedCrossRefGoogle Scholar
  67. 67.
    Theriault M, Dort J, Sutherland G, et al. Local human sural nerve blood flow in diabetic and other polyneuropathies. Brain 1997;120:1131–1138.PubMedCrossRefGoogle Scholar
  68. 68.
    Eaton RP, Qualls C, Bicknell J, Sibbitt WL, King MK, Griffey RH. Structure-function relationships within peripheral nerves in diabetic neuropathy: the hydration hypothesis. Diabetologia 1996;39: 439–446.PubMedCrossRefGoogle Scholar
  69. 69.
    Tesfaye S, Harris N, Jakubowski J, et al. Impaired blood flow and arteriovenous shunting in human diabetic neuropathy: a novel technique of nerve photography and fluorescein angiography. Diabetologia 1993;36:1266–1274.PubMedCrossRefGoogle Scholar
  70. 70.
    Tesfaye S, Malik R, Harris N, Jakubowski J, Mody C, Ward JD. Arteriovenous shunting and proliferating new vessels in acute painful neuropathy of rapid glycaemic control (insulin neuritis). Diabetologia 1996;39:329–335.PubMedCrossRefGoogle Scholar
  71. 71.
    Beggs J, Johnson PC, Olafsen A, Watkins CL, Cleary C. Transperineurial arterioles in human sural nerve. J Neuropathol Exp Neurol 1991;6:704–718.CrossRefGoogle Scholar
  72. 72.
    Kihara M, Mitsui M, Nishikawa S, Nishimoto K, Takahashi M. Comparison of electrophysiological and autonomic tests in sensory diabetic neuropathy. Clin Auton Res 1998;8:213–20.PubMedCrossRefGoogle Scholar
  73. 73.
    Young MJ, Bennett JL, Liderth SA, Veves A, Boulton AJM, Douglas JT. Rheological and microvascular parameters in diabetic peripheral neuropathy. Clin Sci 1996;90:183–187.PubMedGoogle Scholar
  74. 74.
    Ford I, Malik RA, Newrick PG, Preston EF, Ward JD, Greaves M. Relationship between haemostatic factors and capillary morphology in human diabetic neuropathy. Thromb Haemost 1992;68:628–633.PubMedGoogle Scholar
  75. 75.
    Plater ME, Ford I, Dent MT, Preston FE, Ward JD. Elevated von Willebrand factor antigen predicts deterioration in diabetic peripheral nerve function. Diabetologia 1996;39:336–343.PubMedCrossRefGoogle Scholar
  76. 76.
    Jude E, Abbott CA, Young MJ, et al. Potential role of cell adhesion molecules in the pathogenesis of diabetic neuropathy. Diabetologia 1998;41:330–336.PubMedCrossRefGoogle Scholar
  77. 77.
    Sladky JT, Tschoepe RL, Greenberg JH, Brown MJ. Peripheral neuropathy after chronic endoneurial ischaemia. Ann Neurol 1991;29:272–278.PubMedCrossRefGoogle Scholar
  78. 78.
    Nukada H, Dyck PJ. Microsphere embolization of nerve capillaries and fibre degeneration. Am J Pathol 1984;115:275–287.PubMedGoogle Scholar
  79. 79.
    Benstead TJ, Sangalang VE, Dyck PJ. Acute endothelial swelling is induced in endoneurial microvessels by ischaemia. J Neurol Sci 1990;99:37–49.PubMedCrossRefGoogle Scholar
  80. 80.
    Low PA, Schmelzer JD, Ward KK, Yao JK. Experimental chronic hypoxic neuropathy: relevance to diabetic neuropathy. Am J Physiol 1986;250:E94–E99.Google Scholar
  81. 81.
    Benstead TJ, Dyck PJ, Low PA. Chronic hypoxia induces selective maldevelopment of peripheral myelin in rat. J Neuropathol Exp Neurol 1988;47:599–608.PubMedCrossRefGoogle Scholar
  82. 82.
    Tuck RR, Schmelzer JD, Low PA. Endoneurial blood flow and oxygen tension in the sciatic nerves of rats with experimental diabetic neuropathy. Brain 1984;107:935–950.PubMedCrossRefGoogle Scholar
  83. 83.
    Cameron NE, Cotter MA, Low PA. Nerve blood flow in early experimental diabetes in rats: relation to conduction deficits. Am J Physiol 1991;261:E1–E8.Google Scholar
  84. 84.
    Stevens EJ, Carrington AL, Tomlinson DR. Nerve ischaemia in diabetic rats: time-course of development, effect of insulin treatment plus comparison of streptozotocin and BB models. Diabetologia 1994; 37:43–48.PubMedCrossRefGoogle Scholar
  85. 85.
    Williamson JR, Chang K, Frangos M, et al. Hyperglycaemic pseudohypoxia and diabetic complications. Diabetes 1993;42:801–813.PubMedCrossRefGoogle Scholar
  86. 86.
    Ido Y, Chang K, LeJeune W, Tilton RG, Monafo WW, Williamson JR. Diabetes impairs sciatic nerve hyperemia induced by surgical trauma: implications for diabetic neuropathy. Am J Physiol 1997;273: E 174-E 184.Google Scholar
  87. 87.
    Rayman G, Malik RA, Sharma AK, Day JL. Microvascular response to tissue injury and capillary ultrastructure in the foot skin of type I diabetic patients. Clin Sci 1995;89:467–474.PubMedGoogle Scholar
  88. 88.
    Low PA, Tuck RR, Dyck PJ, Schmelzer JD, Yao JK. Prevention of some electrophysiologic and biochemical abnormalities with oxygen supplementation in experimental diabetic neuropathy. Proc Natl Acad Sci USA 1984;81:6894–6898.PubMedCrossRefGoogle Scholar
  89. 89.
    Low PA, Schmelzer JD, Ward KK, Curran GL, Poduslo JF. Effect of hyperbaric oxygenation on normal and chronic streptozotocin diabetic peripheral nerves. Exp Neurol 1985;99:201–212.CrossRefGoogle Scholar
  90. 90.
    Robertson S, Cameron NE, Cotter MA. The effect of calcium antagonist nifedipine on peripheral nerve function in streptozotocin-diabetic rats. Diabetologia 1992;35:1113–1107.PubMedCrossRefGoogle Scholar
  91. 91.
    Cameron NE, Cotter MA, Ferguson K, Robertson S, Radcliffe MA. Effects of chronic alpha-adrenergic receptor blockade on peripheral nerve conduction, hypoxic resistance, polyols, Na+-K+-ATPase activity and vascular supply in STZ-D rats. Diabetes 1991;40:1652–1658.PubMedCrossRefGoogle Scholar
  92. 92.
    Hotta N, Kakuta H, Fakasawa H, et al. Effect of niceritrol on streptozotocin-induced diabetic neuropathy in rats. Diabetes 1992;41:587–591.PubMedCrossRefGoogle Scholar
  93. 93.
    Ristic H, Wiley JW, Hall KE, Sima AAF. Failure of nimodipine to prevent or correct the long-term nerve conduction defect and increased neuronal Ca(2+) currents in the diabetic BB/W rat. Diabetes Res Clin Pract 1996;32:135–140.PubMedCrossRefGoogle Scholar
  94. 94.
    Cotter MA, Cameron NE. Correction of neurovascular deficits in diabetic rats by beta2-adrenoceptor agonist and alpha1-adrenoceptor antagonist treatment: interactions with the nitric oxide system. Eur J Pharmacol 1998;343:217–223.PubMedCrossRefGoogle Scholar
  95. 95.
    Obrosova IG, Van Huysen C, Stevens MJ, Greene DA. Evaluation of a1-adrenoceptor antagonist on diabetes induced changes in nerve function, metabolism, and antioxidative defense. Diabetes 1999;48: 0229.Google Scholar
  96. 96.
    Cameron NE, Cotter MA, Robertson S. Angiotensin converting enzyme inhibition prevents the development of muscle and nerve dysfunction and stimulates angiogenesis in streptozotocin-diabetic rats. Diabetologia 1992;35:12–18.PubMedCrossRefGoogle Scholar
  97. 97.
    Maxfield EK, Cameron NE, Cotter MA, Dines KC. Angiotensin II receptor blockade improves nerve function, modulates nerve blood flow and stimulates endoneurial angiogenesis in streptozotocindiabetic rats. Diabetologia 1993;36:1230–1237.PubMedCrossRefGoogle Scholar
  98. 98.
    Cameron NE, Cotter MA. Effects of a nonpeptide endothelin-1 ETA antagonist on neurovascular function in diabetic rats: interaction with therenin-angiotensin system. J Pharmacol Exp Ther 1996;278: 1262–1268.PubMedGoogle Scholar
  99. 99.
    Yagihashi S, Kamijo M, Baba M, Yagihashi N, Nagai K. Effect of aminoguanidine on functional and structural abnormalities in peripheral nerve of STZ-induced diabetic rats. Diabetes 1992;41:47–52.PubMedCrossRefGoogle Scholar
  100. 100.
    Sugimoto K, Yagihashi S. Effects of aminoguanidine on structural alterations of microvessels in peripheral nerve of streptozotocin diabetic rats. Microvasc Res 1997;53:105–112.PubMedCrossRefGoogle Scholar
  101. 101.
    Bravenboer B, Kappelle AC, Hamers FPT, van Buren T, Erkelens DW, Gispen WH. Potential use of glutathione for the prevention and treatment of diabetic neuropathy in the streptozotocin induced diabetic rat. Diabetologia 1992;35:813–817.PubMedCrossRefGoogle Scholar
  102. 102.
    Low PA, Nickander KK Oxygen free radical effects in sciatic nerve in experimental diabetes. Diabetes 199;40:873–877.Google Scholar
  103. 103.
    Cameron NE, Cotter MA, Archibald V, Dines KC, Maxfield EK. Anti-oxidant and pro-oxidant effects on nerve conduction velocity, endoneurial blood flow and oxygen tension in non-diabetic and streptozotocin diabetic rats. Diabetologia 1994;37:449–459.PubMedCrossRefGoogle Scholar
  104. 104.
    Cameron NE, Cotter MA. Effects of the iron chelator, hydroxy-ethyl starch deferoxamine, on nerve conduction and blood flow in diabetic rats. Diabetes 1999;48:0230.Google Scholar
  105. 105.
    Cameron NE, Cotter MA, Horrobin DH, Tritschler HJ. Effects of alpha-lipoic acid on neurovascular function in diabetic rats: interaction with essential fatty acids. Diabetologia 1998;4:390–399.CrossRefGoogle Scholar
  106. 106.
    Hounsom L, Horrobin DF, Tritschler H, Corder R, Tomlinson DR. A lipoic acid-gamma linolenic acid conjugate is effective against multiple indices of experimental diabetic neuropathy. Diabetologia 1998; 41:839–843.PubMedCrossRefGoogle Scholar
  107. 107.
    Qiang X, Satoh J, Sagara M, et al. Inhibitory effect of troglitazone on diabetic neuropathy in streptozotocin-induced diabetic rats. Diabetologia 1998;41:1321–1326.PubMedCrossRefGoogle Scholar
  108. 108.
    Walker AB, Chattington PD, Buckingham RE, Williams G. The thiazolidinedione rosiglitazone (B RI- 49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes 1999;48:1448–1453.PubMedCrossRefGoogle Scholar
  109. 109.
    Cameron NE, Cotter MA, Jack AM, Basso MD, Hohman TC. Protein kinase C effects on nerve function, perfusion, Na+,K+-ATPase activity and glutathione content in diabetic rats. Diabetologia 1999;42: 1120–1130.PubMedCrossRefGoogle Scholar
  110. 110.
    Nakamura J, Kato K, Hamada Y, et al. A protein kinase C-β-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes 1999;48:2090–2095.PubMedCrossRefGoogle Scholar
  111. 111.
    Young MJ, Veves A, Walker MG, Boulton AJM. Correlations between nerve function and tissue oxygenation in diabetic patients: further clues to the aetiology of diabetic neuropathy? Diabetologia 1992; 35:1146–1150.PubMedCrossRefGoogle Scholar
  112. 112.
    Veves A, Donaghue VM, Samow MR, Giurini JM, Campbell DR, LoGerfo FW. The impact of reversal of hypoxia by revascularization on the peripheral nerve function of diabetic patients. Diabetologia 1996;39:344–348.PubMedCrossRefGoogle Scholar
  113. 113.
    Akbari CM, Gibbons GW, Habershaw GM, LoGerfo FW, Veves A. The effect of arterial reconstruction on the natural history of diabetic neuropathy. Arch Surg 1997;132:148–152.PubMedCrossRefGoogle Scholar
  114. 114.
    Horrobin D. Gamma-linolenic acid in the treatment of diabetic neuropathy. In: Boulton AJM, ed. Diabetic Neuropathy. Marius Press, Exeter, UK, 1997, pp. 183–195.Google Scholar
  115. 115.
    Ziegler D. Reljanovic M, Hanefeld M, et al. Alpha lipoic acid in the treatment of diabetic polyneuropathy in Germany and current evidence from clinical trials. Exp Clin Endocrinol Diabetes 1999;107: 421–430.PubMedCrossRefGoogle Scholar
  116. 116.
    Reja A, Tesfaye S, Harris N, Ward JD. Improvement in nerve conduction and quantitative sensory tests after treatment with lisinopril. Diabetes Med 1995;12:307–309.CrossRefGoogle Scholar
  117. 117.
    Al-Memar A, Wimalaratna HSK, Millward BA. Lisinopril improves nerve function in insulin-dependent diabetic patients with neuropathy: a preferential effect on small fibres. Diabetic Med 1996;S38–P90.Google Scholar
  118. 118.
    Malik RA, Williamson S, Abbott CA, et al. Effect of angiotensin-converting enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet 1998;352: 1978–1981.PubMedCrossRefGoogle Scholar
  119. 119.
    Tesfaye S, Malik RA, Ward JD. Vascular factors in diabetic neuropathy. Diabetologia 1994;37:847–854.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Rayaz A. Malik
  • Solomon Tesfaye
  • John D. Ward

There are no affiliations available

Personalised recommendations